Learn more

SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD

Overview
  • Total Patents
    20
  • GoodIP Patent Rank
    81,095
About

SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD has a total of 20 patent applications. Its first patent ever was published in 2018. It filed its patents most often in WIPO (World Intellectual Property Organization), China and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are FLATLEY DISCOVERY LAB LLC, FLATLEY DISCOVERY LAB and CASTRO ALFREDO C.

Patent filings in countries

World map showing SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTDs patent filings in countries

Patent filings per year

Chart showing SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Jiang Lei 20
#2 Shang Ke 20
#3 Xu Yuan 20
#4 Shou Jianyong 18
#5 Wu Danyi 15
#6 Feng Zhiyong 14
#7 Zhang Yi 14
#8 Deng Jianwen 11
#9 Xu Xueli 10
#10 Zheng Mingwei 9

Latest patents

Publication Filing date Title
WO2020078362A1 Imidazole aromatic ring compound, preparation method and uses thereof
WO2020078360A1 Preparation and uses of protein receptor kinase inhibitor
CA3114243A1 Preparation of semicarbazide-sensitive amine oxidase inhibitor and use thereof
CA3113732A1 Aromatic heterocyclic compound with kinase inhibitory activity
WO2020025030A1 Preparation and application of aromatic compound having immunoregulatory function
WO2020024997A1 Preparation and application of class of n-containing heterocyclic compounds having immunoregulatory function
CN112062780A Preparation and application of aromatic compound with immunoregulation function
CN111269233A Preparation and application of imidazo aromatic ring compounds
CN111171020A Hexa-membered and hexa-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors
CN111171019A Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors
CN109400522A A kind of compound with PD-L1 inhibitory activity, preparation method and the usage